Lannett launches generic Dantrium
Lannett has entered into a three-year agreement with Elite Pharmaceuticals to be the exclusive United States distributor of dantrolene capsules in dosages of 25 mg, 50 mg and 100 mg.
The product is the generic of Par Pharmaceuticals’ Dantrium capsules.
Dantrolene capsules 25 mg, 50 mg and 100 mg had a market value of approximately $6.4 million for the 12 months ended April 2019, according to IQVIA, although actual generic market values are expected to be lower.
“We have commenced the distribution of dantrolene, for which the market is currently comprised of a small number of competitors,” Lannett CEO Tim Crew said. “While the sales potential for this product is modest, adding dantrolene to our portfolio demonstrates our commitment to our customers and patients, as well as our success in expanding relationships with existing strategic partners. This is our second transaction with Elite.”
Under the agreement, Lannett will primarily provide sales, marketing and distribution support for the product, for which it will receive a share of the profits. Other financial terms were not disclosed.
No comments found